Rosuvastatin Dosing for LDL 131 mg/dL with MAFLD
Start with rosuvastatin 10 mg daily and titrate to 20-40 mg daily based on cardiovascular risk stratification and LDL-C goal achievement. 1
Risk Stratification Determines Intensity
Your patient with MAFLD and LDL-C of 131 mg/dL requires cardiovascular risk assessment to determine appropriate statin intensity. The 2022 AACE/AASLD guideline provides clear targets based on risk categories 1:
Determine Your Patient's Risk Category:
- High CV Risk (LDL-C goal <100 mg/dL): 2+ risk factors with 10-year risk 10-20%, OR diabetes/CKD stage 3 without other risk factors
- Very High CV Risk (LDL-C goal <70 mg/dL): Established CVD, 10-year risk ≥20%, OR diabetes with ≥1 additional risk factor
- Extreme CV Risk (LDL-C goal <55 mg/dL): Progressive CVD, OR CVD plus diabetes/CKD/familial hypercholesterolemia
Recommended Dosing Strategy
Initial dose: Start with rosuvastatin 10 mg daily 2. This moderate-to-high intensity dose is appropriate for most MAFLD patients and provides approximately 42% LDL-C reduction 3, 4.
Titration: If LDL-C goal not achieved after 4 weeks, escalate to rosuvastatin 20 mg or 40 mg daily (high-intensity therapy) 1, 2. High-intensity rosuvastatin (20-40 mg) achieves ≥50% LDL-C reduction and is specifically recommended when maximal ASCVD risk reduction is desired 5.
MAFLD-Specific Considerations
Statins are safe and beneficial in MAFLD. The guideline explicitly states that statins are safe in NAFLD/NASH and should NOT be avoided 1. Recent evidence demonstrates rosuvastatin 10 mg daily significantly reduces hepatic steatosis in MAFLD patients over 52 weeks with favorable safety profile 6. Higher doses (20-40 mg) show greater reduction in liver fat content compared to 5 mg 7.
Critical Safety Exception:
Do NOT use statins in decompensated cirrhosis (Child-Pugh C) 1. Ensure your patient does not have advanced cirrhosis before initiating therapy.
Practical Dosing Algorithm
- Start rosuvastatin 10 mg daily for most patients
- Check LDL-C at 4 weeks 2
- If not at goal:
- High CV risk (goal <100): Increase to 20 mg
- Very high CV risk (goal <70): Increase to 20-40 mg
- Extreme CV risk (goal <55): Use 40 mg
- Add ezetimibe, PCSK9 inhibitor, or bempedoic acid if maximally tolerated statin insufficient 1
Dose Modifications
Asian patients: Start at 5 mg daily due to increased drug exposure; maximum 20 mg daily 2
Severe renal impairment (CrCl <30): Start 5 mg daily; maximum 10 mg daily 2
Drug interactions: Multiple medications require dose caps (see FDA label for complete list) 2
Monitoring
- Lipid panel at 4 weeks to assess response and adherence 1, 2
- Liver enzymes: Transient elevations may occur but typically normalize with continued therapy 6, 8
- Do not discontinue for mild transaminase elevations unless >3x upper limit of normal 2
Common Pitfall
Do not underdose statins in MAFLD patients due to unfounded concerns about hepatotoxicity. The evidence clearly demonstrates safety and hepatic benefit 1, 6, 7. The greater risk is undertreating cardiovascular disease, which is the leading cause of death in MAFLD patients 1.